scispace - formally typeset
M

Michael S. Christodoulou

Researcher at University of Milan

Publications -  69
Citations -  1541

Michael S. Christodoulou is an academic researcher from University of Milan. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 17, co-authored 62 publications receiving 1183 citations. Previous affiliations of Michael S. Christodoulou include Agricultural University of Athens & University of Modena and Reggio Emilia.

Papers
More filters
Journal ArticleDOI

The 1,2,3-triazole ring as a bioisostere in medicinal chemistry

Elisa Bonandi, +5 more
- 01 Oct 2017 - 
TL;DR: An overview of the 1,2,3-triazole ring as a bioisostere for the design of drug analogs, highlighting relevant recent examples.
Journal ArticleDOI

Novel pyrazole derivatives: synthesis and evaluation of anti-angiogenic activity.

Michael S. Christodoulou, +3 more
- 15 Jun 2010 - 
TL;DR: Compounds containing the fused pyrazolo[4,3-c]quinoline motifs emerged as potent anti-angiogenic compounds, which also had the ability to inhibit the growth of human breast and cervical carcinoma cells in vitro.
Journal ArticleDOI

Chemical approaches to targeting drug resistance in cancer stem cells.

Panagiota A. Sotiropoulou, +4 more
- 01 Oct 2014 - 
TL;DR: The mechanisms underlying CSC resistance, the potential biological targets to overcome resistance and the chemical compounds showing activity against different types of CSC are summarized.
Journal ArticleDOI

Enzymatic Kinetic Resolution of 2-Piperidineethanol for the Enantioselective Targeted and Diversity Oriented Synthesis.

Dario Perdicchia, +5 more
- 24 Dec 2015 - 
TL;DR: Both synthetic and enzymatic methods for the resolution of the racemic 1 are presented, as well as an overview of synthesized natural products starting from the enantiopure 1.
Journal ArticleDOI

Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors.

Michael S. Christodoulou, +6 more
- 01 Mar 2011 - 
TL;DR: Compounds of the tetrahydrobenzothiazole series were inhibitors of the p53 transcriptional activity and were effective in enhancing paclitaxel-induced apoptosis and the therapeutic interest of the compounds of the former series in combination with taxanes was confirmed in a human tumor xenograft model.